
Simona De Summa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2206556/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets and Therapy, 2016, Volume 9, 7355-7365.	1.0	142
2	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370.	0.6	89
3	GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data. BMC Bioinformatics, 2017, 18, 119.	1.2	79
4	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers, 2020, 12, 3380.	1.7	71
5	Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. Frontiers in Genetics, 2020, 11, 641.	1.1	71
6	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biology and Therapy, 2016, 17, 400-406.	1.5	67
7	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	1.7	66
8	BRCAness: a deeper insight into basal-like breast tumors. Annals of Oncology, 2013, 24, viii13-viii21.	0.6	54
9	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget, 2015, 6, 471-483.	0.8	51
10	Unclassified variants in BRCA genes: guidelines for interpretation. Annals of Oncology, 2011, 22, i18-i23.	0.6	50
11	Exhaled breath condensate biomarkers for lung cancer. Journal of Breath Research, 2019, 13, 044002.	1.5	41
12	KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. Cancers, 2019, 11, 1145.	1.7	33
13	Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumor Biology, 2016, 37, 6143-6153.	0.8	32
14	HOX gene methylation status analysis in patients with hereditary breast cancer. Journal of Human Genetics, 2013, 58, 51-53.	1.1	30
15	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. Journal of Clinical Medicine, 2021, 10, 3567.	1.0	30
16	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. Expert Opinion on Therapeutic Targets, 2015, 19, 1027-1035.	1.5	27
17	P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. Cell Death and Disease, 2020, 11, 748.	2.7	27
18	miRNAs as Key Players in the Management of Cutaneous Melanoma. Cells, 2020, 9, 415.	1.8	23

SIMONA DE SUMMA

#	Article	IF	CITATIONS
19	DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families. Molecular Biotechnology, 2012, 52, 8-15.	1.3	22
20	miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Oncotarget, 2016, 7, 80363-80372.	0.8	21
21	u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer, 2017, 17, 215.	1.1	20
22	Standardization of CTC ARâ€V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Prostate, 2019, 79, 54-61.	1.2	20
23	TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget, 2017, 8, 50715-50723.	0.8	20
24	Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study. Journal of Medical Internet Research, 2020, 22, e19152.	2.1	20
25	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biology of Blood and Marrow Transplantation, 2018, 24, 608-613.	2.0	19
26	Molecular alterations in basal cell carcinoma subtypes. Scientific Reports, 2021, 11, 13206.	1.6	19
27	Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants. Archives of Dermatological Research, 2015, 307, 495-503.	1.1	18
28	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death and Disease, 2014, 5, e1076-e1076.	2.7	17
29	MicroRNA expression profiling in male and female familial breast cancer. British Journal of Cancer, 2014, 111, 2361-2368.	2.9	16
30	miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. Tumor Biology, 2016, 37, 5503-5513.	0.8	16
31	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. PLoS ONE, 2014, 9, e112025.	1.1	15
32	The value of new high-throughput technologies for diagnosis and prognosis in solid tumors. Cancer Biomarkers, 2014, 14, 103-117.	0.8	15
33	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 453-461.	1.5	15
34	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer, 2018, 18, 552.	1.1	14
35	Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. Frontiers in Oncology, 2020, 10, 590707.	1.3	14
36	DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer. Current Molecular Medicine, 2014, 14, 45-57.	0.6	14

SIMONA DE SUMMA

#	Article	IF	CITATIONS
37	Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. Breast Cancer Research and Treatment, 2010, 124, 875-878.	1.1	11
38	<i>BRCA1â€2</i> diagnostic workflow from nextâ€generation sequencing technologies to variant identification and final report. Genes Chromosomes and Cancer, 2016, 55, 803-813.	1.5	11
39	VEGF and TWIST1 in a 16â€biomarker immunoprofile useful for prognosis of breast cancer patients. International Journal of Cancer, 2017, 141, 1901-1911.	2.3	10
40	Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. Journal of Translational Medicine, 2014, 12, 319.	1.8	9
41	BRCA germline mutation test for all woman with ovarian cancer?. BMC Cancer, 2019, 19, 641.	1.1	9
42	Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family. Oncotarget, 2017, 8, 29751-29759.	0.8	8
43	Improvable Lifestyle Factors in Lymphoma Survivors. Acta Haematologica, 2018, 139, 235-237.	0.7	7
44	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	0.8	6
45	Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin's Lymphoma Survivors. Journal of Personalized Medicine, 2021, 11, 215.	1.1	5
46	Adipokines in hereditary breast cancer patients and healthy relatives. Oncotarget, 2017, 8, 101255-101261.	0.8	5
47	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. Oncotarget, 2015, 6, 27865-27879.	0.8	5
48	Genetic risk transmission in a family affected by familial breast cancer. Journal of Human Genetics, 2014, 59, 51-53.	1.1	4
49	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	1.7	4
50	Comment on â€~Renewed interest in the progesterone receptor in breast cancer'. British Journal of Cancer, 2017, 117, e1-e1.	2.9	3
51	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. Diagnostics, 2021, 11, 975.	1.3	3
52	Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. Cancers, 2021, 13, 4714.	1.7	3
53	Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncology Letters, 2020, 20, 2469-2476.	0.8	3
54	A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. Medicina (Lithuania), 2021, 57, 1241.	0.8	3

SIMONA DE SUMMA

#	Article	IF	CITATIONS
55	Innovative technology for cancer risk analysis. Annals of Oncology, 2011, 22, i37-i43.	0.6	2
56	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. Oncology Letters, 2017, 14, 4384-4390.	0.8	2
57	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. International Journal of Molecular Sciences, 2021, 22, 2227.	1.8	2
58	Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. Diagnostics, 2022, 12, 682.	1.3	2
59	BRCA Unclassified Variants: How Can They be Classified?. Current Women's Health Reviews, 2012, 8, 30-37.	0.1	1
60	444: Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. European Journal of Cancer, 2014, 50, S107.	1.3	0
61	Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation. Annals of Oncology, 2015, 26, vi26.	0.6	0
62	MiRNAs modulate gastric cancer drug response by affecting hypoxia signaling. Annals of Oncology, 2015, 26, vi99.	0.6	0
63	40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center. Journal of Thoracic Oncology, 2016, 11, S72.	0.5	0
64	P1.04-58 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell. Journal of Thoracic Oncology, 2019, 14, S463-S464.	0.5	0